MTOR and ovarian carcinoma: Recent research showed that high-dose intravenous ascorbate as an adjuvant could improve chemosensitivity and relieve the toxicity of chemotherapy for ovarian cancer, which was related to an activation of the ATM/AMPK pathway and inhibition of mTOR signaling due to DNA damage and ATP depletion triggered by ascorbate-generated ROS (18).